This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Active Biotech's Partner Teva Initiates A Further Clinical Trial In Multiple Sclerosis

LUND, Sweden, Nov. 4, 2013 (GLOBE NEWSWIRE) --
Active  Biotech  (NASDAQ  OMX NORDIC: ACTI)
announced  today  that  its  partner  Teva Pharmaceutical Industries Ltd. (NYSE:
TEVA)  will  initiate  a  further  clinical  trial,  LIBRETTO,  to  evaluate the
efficacy,  safety and tolerability of two doses of oral laquinimod (0.6 and 1.2
mg/day),  compared to  interferon beta-1a, in  patients with relapsing remitting
multiple  sclerosis. Primary  endpoint of  the study  will be brain atrophy. For
further  details please see where the  trial will appear
during this week.

About laquinimod
Laquinimod  is an oral, investigational, CNS-active immunomodulator with a novel
mechanism  of action being developed for the treatment of relapsing-remitting MS
(RRMS).  The  global  Phase  III  clinical  development  program evaluating oral
laquinimod  in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase
III  laquinimod trial, CONCERTO, is evaluating  two doses of the investigational
product  (0.6mg and 1.2mg) in approximately  1,800 patients for up to 24 months.
The  primary outcome measure will be time to confirmed disability progression as
measured by the EDSS.

In  addition to the  MS clinical studies,  laquinimod has concluded  Phase II of
development  for  Crohn's  disease  and  lupus  nephritis.   Further studies are
planned  to determine the effectiveness of  laquinimod in treating patients with
Huntington's disease and Alzheimer's disease.

About Active Biotech
Active  Biotech AB  (NASDAQ OMX  NORDIC: ACTI)  is a  biotechnology company with
focus  on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are   laquinimod,   an   orally   administered   small   molecule   with  unique
immunomodulatory properties for the treatment of multiple sclerosis, tasquinimod
for prostate cancer and ANYARA primarily for the treatment of renal cell cancer.
In  addition,  laquinimod  has  concluded  Phase  II development for Crohn's and
Lupus.  The company also has one additional project in clinical development, the
orally  administered compound paquinimod  (57-57) for systemic sclerosis. Please
visit for more information.

For further information:

Tomas Leanderson, President & CEO
Tel: +46 46 19 20 95

  Active Biotech AB (Corp. Reg. No. 556223-9227)
  Box 724, SE-220 07 Lund
  Tel: +46 46 19 20 00
  Fax: +46 46 19 11 00

Active Biotech's Safe Harbor Statement in Accordance with the Swedish Securities
Market Act
This  press release  contains certain  forward-looking statements. Such forward-
looking  statements  involve  known  and  unknown risks, uncertainties and other
important   factors   that  could  cause  the  actual  results,  performance  or
achievements  of the company, or industry results, to differ materially from any
future  results,  performance  or  achievement  implied  by  the forward-looking
statements.  The company does not undertake any obligation to update or publicly
release   any   revisions  to  forward-looking  statements  to  reflect  events,
circumstances or changes in expectations after the date of this press release.

Active  Biotech is obligated to publish  the information contained in this press
release  in accordance with the Swedish  Securities Market Act. This information
was provided to the media for publication 08:30 am CET on November 4, 2013.

Active Biotech's partner Teva initiates a further clinical trial :


Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs